E4512 – A Phase III Double-Blinded Trial for Surgically Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Lung cancer, Surgically Removed
2. WHO IS ELIGIBLE?
Patinets who have an ALK mutation.
3. HOW WILL I BE TREATED?
Patients may get Crizonitib (a drug approved for ALK+ lung cancer).
For Physicians: More information about this specific trial at clinicaltrials.gov